UK start­up tack­les hot neoanti­gen field in can­cer drugs

Can­cer Re­search UK and the Na­tion­al In­sti­tute for Health Re­search have come to­geth­er to back a $17.5 mil­lion round for a new up­start en­ter­ing the in­creas­ing­ly hot neoanti­gen field.

The new biotech is called Achilles Ther­a­peu­tics, and it’s work­ing on de­vel­op­ing can­cer drugs based on the in­sights of sev­er­al ex­perts from top aca­d­e­m­ic groups in the coun­try. Their fo­cus is on trun­cal tu­mor neoanti­gens, with a spot­light on lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER